LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 276

Search options

  1. Book: Changing patterns in the treatment of type 2 diabetes

    Pratley, Richard E.

    (The American journal of medicine ; 126,9A = Suppl.)

    2013  

    Author's details guest ed. Richard E. Pratley
    Series title The American journal of medicine ; 126,9A = Suppl.
    Collection
    Language English
    Size S48 S. : graph. Darst.
    Publisher Elsevier
    Publishing place New York, NY
    Publishing country United States
    Document type Book
    HBZ-ID HT017781848
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Ua VI Zs 289 -126,9A- verfügbar in Königswinter Königswinter

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Newer Glucose-Lowering Therapies in Older Adults with Type 2 Diabetes.

    Bilal, Anika / Pratley, Richard E

    Endocrinology and metabolism clinics of North America

    2023  Volume 52, Issue 2, Page(s) 355–375

    Abstract: Diabetes is prevalent in older adults and older adults with diabetes are more likely to have multiple comorbidities. It is, therefore, important to personalize diabetes management in this group. Newer glucose-lowering drugs, including dipeptidyl ... ...

    Abstract Diabetes is prevalent in older adults and older adults with diabetes are more likely to have multiple comorbidities. It is, therefore, important to personalize diabetes management in this group. Newer glucose-lowering drugs, including dipeptidyl peptidase-4 inhibitors, sodium-glucose cotransporter 2 inhibitors, and glucagon-like peptide-1 receptor agonists can be safely used in older patients and are preferred choices in many cases due to their safety, efficacy, and low risk of hypoglycemia.
    MeSH term(s) Humans ; Aged ; Diabetes Mellitus, Type 2/drug therapy ; Hypoglycemic Agents/adverse effects ; Glucose/therapeutic use ; Sodium-Glucose Transporter 2 Inhibitors/therapeutic use ; Dipeptidyl-Peptidase IV Inhibitors/adverse effects
    Chemical Substances Hypoglycemic Agents ; Glucose (IY9XDZ35W2) ; Sodium-Glucose Transporter 2 Inhibitors ; Dipeptidyl-Peptidase IV Inhibitors
    Language English
    Publishing date 2023-02-20
    Publishing country United States
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 92116-6
    ISSN 1558-4410 ; 0889-8529
    ISSN (online) 1558-4410
    ISSN 0889-8529
    DOI 10.1016/j.ecl.2022.10.010
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Se 148: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Can technology improve the management of older adults with type 1 diabetes? Yes, but….

    Pratley, Richard E / Casu, Anna

    The Lancet. Healthy longevity

    2022  Volume 3, Issue 3, Page(s) e120–e121

    MeSH term(s) Aged ; Attitude to Computers ; Diabetes Mellitus, Type 1/therapy ; Humans ; Technology
    Language English
    Publishing date 2022-02-23
    Publishing country England
    Document type Journal Article
    ISSN 2666-7568
    ISSN (online) 2666-7568
    DOI 10.1016/S2666-7568(22)00032-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Article ; Online: Closed-loop therapy in older adults with type 1 diabetes: hypoglycaemia benefits and risk stratification - Authors' reply.

    Pratley, Richard E / Casu, Anna

    The Lancet. Healthy longevity

    2022  Volume 3, Issue 6, Page(s) e379

    MeSH term(s) Aged ; Diabetes Mellitus, Type 1/drug therapy ; Humans ; Hypoglycemia/chemically induced ; Insulin Infusion Systems ; Risk Assessment
    Language English
    Publishing date 2022-06-09
    Publishing country England
    Document type Letter
    ISSN 2666-7568
    ISSN (online) 2666-7568
    DOI 10.1016/S2666-7568(22)00112-X
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  5. Article ; Online: Closed-loop therapy in older adults with type 1 diabetes

    Richard E Pratley / Anna Casu

    The Lancet. Healthy Longevity, Vol 3, Iss 6, Pp e379- (2022)

    hypoglycaemia benefits and risk stratification – Authors' reply

    2022  

    Keywords Geriatrics ; RC952-954.6 ; Medicine ; R
    Language English
    Publishing date 2022-06-01T00:00:00Z
    Publisher Elsevier
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  6. Article ; Online: Implications of cardiovascular outcome trials with injectable antidiabetic agents.

    Pratley, Richard E

    Journal of diabetes

    2018  Volume 10, Issue 10, Page(s) 801–803

    MeSH term(s) Cardiovascular Diseases/etiology ; Cardiovascular Diseases/prevention & control ; Clinical Trials as Topic ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/drug therapy ; Humans ; Hypoglycemic Agents/therapeutic use ; Prognosis
    Chemical Substances Hypoglycemic Agents
    Language English
    Publishing date 2018-07-04
    Publishing country Australia
    Document type Journal Article
    ZDB-ID 2503337-2
    ISSN 1753-0407 ; 1753-0393
    ISSN (online) 1753-0407
    ISSN 1753-0393
    DOI 10.1111/1753-0407.12792
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6791: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Indirect treatment comparisons: Choosing the right tool for the job.

    Pratley, Richard E / Gorst-Rasmussen, Anders

    Diabetes, obesity & metabolism

    2022  Volume 24, Issue 6, Page(s) 1180–1181

    MeSH term(s) Diabetes Mellitus, Type 2 ; Glucagon-Like Peptides ; Glycated Hemoglobin A/analysis ; Humans ; Hypoglycemic Agents ; Immunoglobulin Fc Fragments ; Recombinant Fusion Proteins
    Chemical Substances Glycated Hemoglobin A ; Hypoglycemic Agents ; Immunoglobulin Fc Fragments ; Recombinant Fusion Proteins ; Glucagon-Like Peptides (62340-29-8)
    Language English
    Publishing date 2022-02-21
    Publishing country England
    Document type Letter
    ZDB-ID 1454944-x
    ISSN 1463-1326 ; 1462-8902
    ISSN (online) 1463-1326
    ISSN 1462-8902
    DOI 10.1111/dom.14664
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5442: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes.

    Aroda, Vanita R / Blonde, Lawrence / Pratley, Richard E

    Reviews in endocrine & metabolic disorders

    2022  Volume 23, Issue 5, Page(s) 979–994

    Abstract: Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) were first introduced for the treatment of type 2 diabetes (T2D) in 2005. Despite the high efficacy and other benefits of GLP-1RAs, their uptake was initially limited by the fact that they ... ...

    Abstract Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) were first introduced for the treatment of type 2 diabetes (T2D) in 2005. Despite the high efficacy and other benefits of GLP-1RAs, their uptake was initially limited by the fact that they could only be administered by injection. Semaglutide is a human GLP-1 analog that has been shown to significantly improve glycemic control and reduce body weight, in addition to improving cardiovascular outcomes, in patients with T2D. First approved as a once-weekly subcutaneous injection, semaglutide was considered an ideal peptide candidate for oral delivery with a permeation enhancer on account of its low molecular weight, long half-life, and high potency. An oral formulation of semaglutide was therefore developed by co-formulating semaglutide with sodium N-(8-[2-hydroxybenzoyl]amino)caprylate, a well-characterized transcellular permeation enhancer, to produce the first orally administered GLP-1RA. Pharmacokinetic analysis showed that stable steady-state concentrations could be achieved with once-daily dosing owing to the long half-life of oral semaglutide. Upper gastrointestinal disease and renal and hepatic impairment did not affect the pharmacokinetic profile. In the phase III PIONEER clinical trial program, oral semaglutide was shown to reduce glycated hemoglobin and body weight compared with placebo and active comparators in patients with T2D, with no new safety signals reported. Cardiovascular efficacy and safety are currently being assessed in a dedicated outcomes trial. The development of an oral GLP-1RA represents a significant milestone in the management of T2D, providing an additional efficacious treatment option for patients.
    MeSH term(s) Body Weight ; Caprylates/therapeutic use ; Diabetes Mellitus, Type 2/drug therapy ; Glucagon-Like Peptide 1 ; Glucagon-Like Peptide-1 Receptor/agonists ; Glucagon-Like Peptide-1 Receptor/therapeutic use ; Glucagon-Like Peptides/adverse effects ; Glycated Hemoglobin A ; Humans ; Hypoglycemic Agents/therapeutic use ; Peptides/therapeutic use ; Sodium/therapeutic use
    Chemical Substances Caprylates ; Glucagon-Like Peptide-1 Receptor ; Glycated Hemoglobin A ; Hypoglycemic Agents ; Peptides ; semaglutide (53AXN4NNHX) ; Glucagon-Like Peptides (62340-29-8) ; Glucagon-Like Peptide 1 (89750-14-1) ; Sodium (9NEZ333N27)
    Language English
    Publishing date 2022-07-15
    Publishing country Germany
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 2185718-0
    ISSN 1573-2606 ; 1389-9155
    ISSN (online) 1573-2606
    ISSN 1389-9155
    DOI 10.1007/s11154-022-09735-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6069: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Should GLP-1 Receptor Agonists Be the First Line of Treatment for Type 2 Diabetes?

    Pratley, Richard E

    Diabetes technology & therapeutics

    2016  Volume 18, Issue 11, Page(s) 671–673

    Language English
    Publishing date 2016-11
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1452816-2
    ISSN 1557-8593 ; 1520-9156
    ISSN (online) 1557-8593
    ISSN 1520-9156
    DOI 10.1089/dia.2016.0339
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5269: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article: GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials.

    Gilbert, Matthew P / Pratley, Richard E

    Frontiers in endocrinology

    2020  Volume 11, Page(s) 178

    Abstract: The incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are released from enteroendocrine cells in response to the presence of nutrients in the small intestines. These homones facilitate glucose ... ...

    Abstract The incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are released from enteroendocrine cells in response to the presence of nutrients in the small intestines. These homones facilitate glucose regulation by stimulating insulin secretion in a glucose dependent manner while suppressing glucagon secretion. In patients with type 2 diabetes (T2DM), an impaired insulin response to GLP-1 and GIP contributes to hyperglycemia. Dipeptidyl peptidase-4 (DPP-4) inhibitors block the breakdown of GLP-1 and GIP to increase levels of the active hormones. In clinical trials, DPP-4 inhibitors have a modest impact on glycemic control. They are generally well-tolerated, weight neutral and do not increase the risk of hypoglycemia. GLP-1 receptor agonists (GLP-1 RA) are peptide derivatives of either exendin-4 or human GLP-1 designed to resist the activity of DPP-4 and therefore, have a prolonged half-life. In clinical trials, they have demonstrated superior efficacy to many oral antihyperglycemic drugs, improved weight loss and a low risk of hypoglycemia. However, GI adverse events, particularly nausea, vomiting, and diarrhea are seen. Both DPP-4 inhibitors and GLP-1 RAs have demonstrated safety in robust cardiovascular outcome trials, while several GLP-1 RAs have been shown to significantly reduce the risk of major adverse cardiovascular events in persons with T2DM with pre-existing cardiovascular disease (CVD). Several clinical trials have directly compared the efficacy and safety of DPP-4 inhibitors and GLP-1 RAs. These studies have generally demonstrated that the GLP-1 RA provided superior glycemic control and weight loss relative to the DPP-4 inhibitor. Both treatments were associated with a low and comparable incidence of hypoglycemia, but treatment with GLP-1 RAs were invariably associated with a higher incidence of GI adverse events. A few studies have evaluated switching patients from DPP-4 inhibitors to a GLP-1RA and, as expected, improved glycemic control and weight loss are seen following the switch. According to current clinical guidelines, GLP-1RA and DPP-4 inhibitors are both indicated for the glycemic management of patients with T2DM across the spectrum of disease. GLP-1RA may be preferred over DPP- 4 inhibitors for many patients because of the greater reductions in hemoglobin A1c and weight loss observed in the clinical trials. Among patients with preexisting CVD, GLP-1 receptor agonists with a proven cardiovascular benefit are indicated as add-on to metformin therapy.
    MeSH term(s) Clinical Trials as Topic/methods ; Clinical Trials as Topic/statistics & numerical data ; Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 2/epidemiology ; Dipeptidyl-Peptidase IV Inhibitors/therapeutic use ; Drug-Related Side Effects and Adverse Reactions/epidemiology ; Glucagon-Like Peptide 1/analogs & derivatives ; Glucagon-Like Peptide 1/therapeutic use ; Humans ; Hypoglycemic Agents/therapeutic use
    Chemical Substances Dipeptidyl-Peptidase IV Inhibitors ; Hypoglycemic Agents ; Glucagon-Like Peptide 1 (89750-14-1)
    Language English
    Publishing date 2020-04-03
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2592084-4
    ISSN 1664-2392
    ISSN 1664-2392
    DOI 10.3389/fendo.2020.00178
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top